Theratechnologies Past Earnings Performance
Past criteria checks 0/6
Theratechnologies's earnings have been declining at an average annual rate of -5.8%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 6.6% per year.
Key information
-5.8%
Earnings growth rate
0.06%
EPS growth rate
| Biotechs Industry Growth | 51.1% |
| Revenue growth rate | 6.6% |
| Return on equity | n/a |
| Net Margin | -3.7% |
| Last Earnings Update | 31 Aug 2024 |
Recent past performance updates
Recent updates
Increases to CEO Compensation Might Be Put On Hold For Now at Theratechnologies Inc. (TSE:TH)
May 03
Theratechnologies Inc.'s (TSE:TH) Share Price Boosted 25% But Its Business Prospects Need A Lift Too
Apr 10Earnings Update: Theratechnologies Inc. (TSE:TH) Just Reported And Analysts Are Trimming Their Forecasts
Feb 24Investors Don't See Light At End Of Theratechnologies Inc.'s (TSE:TH) Tunnel And Push Stock Down 27%
Feb 07The Market Doesn't Like What It Sees From Theratechnologies Inc.'s (TSE:TH) Revenues Yet
Apr 17Revenue & Expenses Breakdown
How Theratechnologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Aug 24 | 84 | -3 | 36 | 15 |
| 31 May 24 | 83 | -7 | 37 | 18 |
| 29 Feb 24 | 78 | -18 | 37 | 23 |
| 30 Nov 23 | 82 | -24 | 39 | 29 |
| 31 Aug 23 | 80 | -29 | 34 | 35 |
| 31 May 23 | 80 | -36 | 37 | 38 |
| 28 Feb 23 | 81 | -49 | 47 | 38 |
| 30 Nov 22 | 80 | -47 | 48 | 37 |
| 31 Aug 22 | 77 | -49 | 57 | 36 |
| 31 May 22 | 74 | -51 | 55 | 36 |
| 28 Feb 22 | 73 | -35 | 46 | 31 |
| 30 Nov 21 | 70 | -32 | 40 | 28 |
| 31 Aug 21 | 70 | -27 | 42 | 26 |
| 31 May 21 | 66 | -25 | 40 | 22 |
| 28 Feb 21 | 66 | -24 | 40 | 19 |
| 30 Nov 20 | 66 | -23 | 39 | 18 |
| 31 Aug 20 | 63 | -24 | 40 | 15 |
| 31 May 20 | 65 | -18 | 39 | 13 |
| 29 Feb 20 | 64 | -16 | 37 | 14 |
| 30 Nov 19 | 63 | -12 | 35 | 11 |
| 31 Aug 19 | 61 | -7 | 31 | 7 |
| 31 May 19 | 58 | -5 | 29 | 5 |
| 28 Feb 19 | 52 | -4 | 28 | 0 |
| 30 Nov 18 | 45 | -5 | 28 | 0 |
| 31 Aug 18 | 41 | -7 | 28 | 0 |
| 31 May 18 | 36 | -9 | 28 | 0 |
| 28 Feb 18 | 35 | -15 | 27 | 0 |
| 30 Nov 17 | 33 | -14 | 25 | 0 |
| 31 Aug 17 | 33 | -11 | 22 | 0 |
| 31 May 17 | 28 | -8 | 18 | 0 |
| 28 Feb 17 | 28 | -1 | 15 | 0 |
| 30 Nov 16 | 28 | 0 | 15 | 0 |
| 31 Aug 16 | 27 | 1 | 15 | 0 |
| 31 May 16 | 27 | 1 | 15 | 0 |
| 29 Feb 16 | 25 | 2 | 14 | 0 |
| 30 Nov 15 | 23 | 1 | 13 | 0 |
| 31 Aug 15 | 18 | -2 | 11 | 0 |
| 31 May 15 | 12 | -6 | 10 | 0 |
| 28 Feb 15 | 8 | -6 | 10 | -3 |
| 30 Nov 14 | 6 | -9 | 10 | -4 |
| 31 Aug 14 | 5 | -9 | 9 | -4 |
| 31 May 14 | 7 | -7 | 7 | -4 |
| 28 Feb 14 | 7 | -9 | 5 | 0 |
| 30 Nov 13 | 7 | -4 | 4 | 0 |
Quality Earnings: TH is currently unprofitable.
Growing Profit Margin: TH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TH is unprofitable, and losses have increased over the past 5 years at a rate of 5.8% per year.
Accelerating Growth: Unable to compare TH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: TH's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.